Abstract: The present invention relates to chemical compounds which can be used in particular as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting Ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of these compounds as pharmaceutical agents and the use of the pharmaceutical agents for the treatment of tumor diseases.

Abstract: A drug on the basis of 7,19-epoxy steroids, comprising a compound of the general formula (I) or a physiologically acceptable salt thereof, wherein R1=H; methyl, aryl-CH2—, Rx—C(?O)— or Rx—O—C(?O)—, or R1O is dispensed with if there is a double bond between 4-5, W1, W2, independently of each other, represent H, OH, CHR2OH, CHR2Rx, CR2RxOH or W1 and W2 together represent O, R2=saturated or unsaturated, optionally branched alkyl groups with 4 to 9 C atoms, wherein these alkyl groups can also have a cyclopropane or cyclobutane substructure; R3=methyl or ethyl, X1, X2 independently of each other represent Rx or OR5, or together represent O, NOR4; Y1, Y2 independently of each other represent Rx or OR5, or together represent O, NOR4; or X1 and Y1 together form a double bond or an epoxy group; Z1, Z2 independently of each other represent Rx or OR5, or together represent O, NOR4, CH2; R4 independently of each other represent H, alkyl or aryl; and R5 independently of each other represent H; alkyl, aryl-CH2—,

Abstract: The present invention relates to chemical compounds which can be used in particular as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting Ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of these compounds as pharmaceutical agents and the use of the pharmaceutical agents for the treatment of tumor diseases.

Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.

Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.

Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

Abstract: The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes which can deliver carbon monoxide to a physiological target, wherein release of carbon monoxide can be enzymatically-triggered. The present invention also provides for methods of manufacturing the enzymatically-triggered carbon monoxide releasing molecules and methods for their use.

Abstract: Substituted tricyclic diproline analogues of the formula (I): wherein the variables are as defined herein. Also disclosed are methods for the production thereof, the use thereof for the induction of an alpha-helix conformation in peptides and/or proteins, pharmaceuticals containing said compounds, methods for the production of a peptide library containing said compounds, and peptide libraries containing said compounds.

Abstract: The present invention provides a compound comprising a general formula 1: In general formula 1, X is at least one of O and S. A is a ring bridge. Y1 is at least one of H, alkyl, fluoroalkyl, aryl and heteroaryl. Z1, Z2, Z3 are, individually or alternatively, at least one of H, carbonyl, OH, O-alkyl, O-acyl, N—R1R2 (where R1 or R2 are, individually or alternatively, at least one of H, alkyl, acyl, and sulfonyl), alkyl, acyl, fluoroalkyl, aryl, and heteroaryl. R1 is at least one of alkyl, acyl, alkoxycarbonyl, aryloxycarbonyl, and aminocarbonyl. R2 is at least one of H, alkyl, aryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminoacyl and peptidyl. The present invention furthermore relates to the use of the compound as a pharmaceutical active compound, and to the use of the pharmaceutical active compound to treat bacterial diseases, neurodegenerative diseases and tumors.

Abstract: The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumors.

Abstract: The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes which can deliver carbon monoxide to a physiological target, wherein release of carbon monoxide can be enzymatically-triggered. The present invention also provides for methods of manufacturing the enzymatically-triggered carbon monoxide releasing molecules and methods for their use.

Abstract: Substituted tricyclic diproline analogues of the formula (I): wherein the variables are as defined herein. Also disclosed are methods for the production thereof, the use thereof for the induction of an alpha-helix conformation in peptides and/or proteins, pharmaceuticals containing said compounds, methods for the production of a peptide library containing said compounds, and peptide libraries containing said compounds.

Abstract: The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumours.